Tracer library / [68Ga]HTK03149

[68Ga]HTK03149

Also written as [Ga-68]Ga-HTK03149

Radionuclide: Ga-68 t½ 67.71 min
Modality: PET
Production route: —
Stage: Reported once
Syntheses indexed: 1

Prostate cancer Dosimetry and biodistribution studies PSMA-directed radioligand therapy

What it is

Compound class: PSMA-targeting Lys-urea-Glu (urea-based) small-molecule ligand
Target / mechanism: PSMA (prostate-specific membrane antigen) targeting via Lys-urea-Glu pharmacophore PMID 36168623
Clinical application: PSMA-targeted radioligand therapy of prostate cancer (preclinical, proposed for clinical translation) PMID 36168623
Theranostic pair: [177Lu]Lu-HTK03149

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
—	—	HPLC	—	—	HTK03149	36168623 2022 Theranostics

Need this precursor?We can point you to suppliers for [68Ga]HTK03149, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 36168623. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 36168623: 'HTK03161, HTK03149 and HTK03189A/B were obtained by replacing Glu in HTK03041'. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to PET: Ga-68 is a positron emitter used only for PET imaging. Linked articles: PMID 36168623.